DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Rating of “Hold” by Brokerages

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has earned an average recommendation of “Hold” from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.4167.

A number of brokerages have issued reports on XRAY. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target for the company. Barclays lowered their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. UBS Group dropped their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, Mizuho decreased their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $13.46 on Tuesday. The company has a market capitalization of $2.70 billion, a P/E ratio of -4.27, a P/E/G ratio of 1.67 and a beta of 0.89. DENTSPLY SIRONA has a 1-year low of $9.40 and a 1-year high of $17.09. The firm’s 50 day simple moving average is $10.86 and its two-hundred day simple moving average is $11.76. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. During the same period last year, the company earned $0.43 earnings per share. The business’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Brian P. Mckeon acquired 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was acquired at an average cost of $10.12 per share, with a total value of $101,200.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $101,200. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Brian T. Gladden acquired 9,985 shares of DENTSPLY SIRONA stock in a transaction dated Monday, June 15th. The shares were bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the transaction, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 35,160 shares of company stock valued at $351,179 in the last three months. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. First Eagle Investment Management LLC boosted its holdings in shares of DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after purchasing an additional 458,744 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after purchasing an additional 92,868 shares during the last quarter. Southpoint Capital Advisors LP purchased a new stake in shares of DENTSPLY SIRONA in the first quarter worth about $116,000,000. Finally, Armistice Capital LLC lifted its position in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after buying an additional 1,562,000 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.